The medical device Antinitus breaks new ground in tinnitus treatment and research. On January 8th, the results from Sensori’s clinical placebo study of the Antinitus patch have been published in the scientific journal The International Tinnitus Journal. The results show statistically assured and clinically significant relief of tinnitus with Antinitus. The study also confirms that Antinitus is safe and without any risk of serious complications or side effects.
As part of Sensori’s clinical development programme, a double-blind, randomised, parallel and placebo-controlled study of Antinitus was carried out during 2016/2017 by physicians at the Sickla ENT-centre in Stockholm and the Citysjukhuset hospital in Gothenburg. The purpose of the study was to compare the clinical effect of Antinitus with placebo. 82 patients took part in the study. The treatment period was three weeks with a follow-up four weeks after the treatment was completed. A month after the end of treatment, three times as many patients in the Antinitus group experienced relief compared to the placebo group. The difference is statistically assured and the effect clinically significant. The side effects were few, minor and transient and were primarily skin irritations equivalent to those caused by the placebo patches.
The study is now being published in the internationally renown publication The International Tinnitus Journal, a journal specialising in tinnitus research.
‘The publication in the ”The International Tinnitus Journal” means that the placebo study has been critically reviewed by leading and independent scientific experts in the field of tinnitus. The result of the study, and its review, is a great leap forward for Sensori, but primarily positive news for all the people around the world who are living with tinnitus. With Antinitus, they can choose a solution and treatment that show good opportunities for relief and an increased quality of life ‘, says Torbjörn Kemper, Managing director of Sensori AB.
Those behind Antinitus are Swedish physicians and researchers who for over 10 years have searched for answers to how tinnitus can be relieved. Antinitus, a patch that can easily be attached behind the ear, is the result of this work. Today, the product is registered and approved on significant markets, such as Europe, Canada, Australia, New Zealand and Hong Kong.
‘The interest in and publication of the study opens up an assertive global commercialisation of the tinnitus patch and Sensori. This is something that our potential partners/distributors have been waiting for, but above all, I am incredibly proud that we, as a Swedish company, have, after years of product development, developed a tinnitus product with high clinical evidence that can help many of the millions of people suffering from tinnitus worldwide’, says Tommy Rönngren, Founder and Member of the Board at Sensori AB.
